CL2012001304A1 - Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas. - Google Patents

Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas.

Info

Publication number: CL2012001304A1
Authority: CL; Chile
Prior art keywords: antigen; binds; peptide; antibody; human
Prior art date: 2009-11-26

Application number

CL2012001304A

Other languages

English (en)

Inventor

Renfeng Gou

Niels Christoph Riedemann

Yan Li

Beifen Shen

Original Assignee

Inflarx Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-26

Filing date

2012-05-18

Publication date

2012-08-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41683202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001304(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-05-18 Application filed by Inflarx Gmbh filed Critical Inflarx Gmbh

2012-08-03 Publication of CL2012001304A1 publication Critical patent/CL2012001304A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Mycology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Radiology & Medical Imaging (AREA)
Biotechnology (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)

CL2012001304A 2009-11-26 2012-05-18 Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas. CL2012001304A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26469609P	2009-11-26	2009-11-26
EP09014745A EP2327725A1 (en)	2009-11-26	2009-11-26	Anti-C5a binding moieties with high blocking activity

Publications (1)

Publication Number	Publication Date
CL2012001304A1 true CL2012001304A1 (es)	2012-08-03

Family

ID=41683202

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012001304A CL2012001304A1 (es)	2009-11-26	2012-05-18	Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas.

Country Status (29)

Country	Link
US (4)	US8802096B2 (es)
EP (4)	EP2327725A1 (es)
JP (4)	JP6104605B2 (es)
KR (3)	KR102112969B1 (es)
CN (2)	CN102741283B (es)
AU (1)	AU2010324141B2 (es)
BR (1)	BR112012012514B1 (es)
CA (1)	CA2780520C (es)
CL (1)	CL2012001304A1 (es)
CY (2)	CY1118463T1 (es)
DK (2)	DK2504362T3 (es)
EA (1)	EA022759B1 (es)
ES (2)	ES2773725T3 (es)
FR (1)	FR25C1024I1 (es)
HR (2)	HRP20170041T1 (es)
HU (2)	HUE049376T2 (es)
IL (1)	IL219911A (es)
LT (2)	LT3181582T (es)
MX (1)	MX2012006060A (es)
NL (1)	NL301334I2 (es)
NZ (1)	NZ600348A (es)
PE (1)	PE20130314A1 (es)
PH (1)	PH12012501243A1 (es)
PL (2)	PL2504362T3 (es)
PT (2)	PT2504362T (es)
RS (2)	RS59955B1 (es)
SI (2)	SI2504362T1 (es)
SM (3)	SMT202000106T1 (es)
WO (1)	WO2011063980A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007114319A1 (ja)	2006-03-31	2007-10-11	Chugai Seiyaku Kabushiki Kaisha	抗体の血中動態を制御する方法
EP3127921A1 (en)	2007-09-26	2017-02-08	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substition in cdr
EP2708559B1 (en)	2008-04-11	2018-03-28	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US8703129B2 (en)	2008-09-07	2014-04-22	GlycoNex, Inc.	Antibodies against extended type 1 chain antigens, derivatives thereof and use
EP2327725A1 (en)	2009-11-26	2011-06-01	InflaRx GmbH	Anti-C5a binding moieties with high blocking activity
EA028899B1 (ru)	2010-04-30	2018-01-31	Алексион Фармасьютикалз, Инк.	АНТИ-C5a-АНТИТЕЛА И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ
TWI654204B (zh)	2010-11-30	2019-03-21	中外製藥股份有限公司	具有鈣依存性的抗原結合能力之抗體
US10039802B2 (en)	2011-06-22	2018-08-07	Apellis Pharmaceuticals, Inc.	Methods of treating chronic disorders with complement inhibitors
HRP20190522T1 (hr) *	2012-02-20	2019-05-03	Swedish Orphan Biovitrum Ab (Publ)	Polipeptidi koji se vežu za humani komplement c5
EP2666785A1 (en)	2012-05-23	2013-11-27	Affiris AG	Complement component C5a-based vaccine
DK3038633T3 (da)	2013-08-28	2021-01-11	Ipc Res Llc	Stabile polypeptider der binder til human komplement c5
CN105473606A (zh)	2013-08-28	2016-04-06	阿菲博迪公司	具有突变的支架的结合多肽
US9603927B2 (en)	2014-02-28	2017-03-28	Janssen Biotech, Inc.	Combination therapies with anti-CD38 antibodies
US9732154B2 (en)	2014-02-28	2017-08-15	Janssen Biotech, Inc.	Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
KR20160127042A (ko) *	2014-03-20	2016-11-02	인플라알엑스 게엠베하	바이러스성 폐렴의 치료를 위한 c5a의 억제제
MX386886B (es)	2014-09-09	2025-03-12	Janssen Biotech Inc	Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
EA037084B9 (ru)	2014-12-04	2021-08-05	Янссен Байотек, Инк.	Антитела к cd38 для лечения острого миелолейкоза
ES2899894T3 (es)	2014-12-19	2022-03-15	Chugai Pharmaceutical Co Ltd	Anticuerpos anti-C5 y métodos de uso
CA2963760A1 (en)	2014-12-19	2016-06-23	Yoshinao Ruike	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016187546A1 (en)	2015-05-20	2016-11-24	Janssen Biotech, Inc.	Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
AU2016282674B2 (en)	2015-06-22	2022-01-13	Janssen Biotech, Inc.	Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en)	2015-06-24	2017-02-16	Janssen Biotech, Inc.	Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CA3004152C (en)	2015-11-03	2024-04-16	Janssen Biotech, Inc.	Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en)	2015-11-03	2020-09-22	Janssen Biotech, Inc.	Subcutaneous formulations of anti-CD38 antibodies and their uses
CN106957366B (zh) *	2016-01-12	2022-02-01	上海昀怡健康科技发展有限公司	一种C5aR抗体及其制备方法和应用
EP3454902A4 (en) *	2016-05-10	2019-10-09	Annexon, Inc.	ANTI-COMPLEMENT FACTOR C4 / C4B ANTIBODIES AND USES THEREOF
KR102667023B1 (ko)	2016-06-14	2024-05-21	리제너론 파아마슈티컬스, 인크.	항-c5 항체 및 이의 용도
JP2019527678A (ja)	2016-06-28	2019-10-03	ユーエムセー・ユトレヒト・ホールディング・ベー・フェー	ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
TWI831965B (zh)	2016-08-05	2024-02-11	日商中外製藥股份有限公司	Il-8相關疾病之治療用或預防用組成物
WO2018165062A1 (en) *	2017-03-06	2018-09-13	The Trustees Of The University Of Pensylvania	Anti-c5 antibodies and uses thereof
SG11201908744PA (en) *	2017-03-23	2019-10-30	Univ Pennsylvania	Anti-c5a antibodies and uses thereof
US10376595B2 (en)	2017-04-03	2019-08-13	Inflarx Gmbh	Treatment of inflammatory diseases with inhibitors of C5a activity
AU2018249310A1 (en)	2017-04-03	2019-10-17	Inflarx Gmbh	Treatment of inflammatory diseases with inhibitors of C5a activity
SG11201912882QA (en)	2017-06-23	2020-01-30	Inflarx Gmbh	Treatment of inflammatory diseases with inhibitors of c5a activity
CA3079242A1 (en)	2017-10-31	2019-05-09	Janssen Biotech, Inc.	Methods of treating high risk multiple myeloma
SG11202004662RA (en)	2017-12-13	2020-06-29	Regeneron Pharma	Anti-c5 antibody combinations and uses thereof
EP3586865A1 (en)	2018-06-21	2020-01-01	Charité - Universitätsmedizin Berlin	Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
CN109053882B (zh) *	2018-08-28	2019-08-23	东莞市朋志生物科技有限公司	一种ns1蛋白的结合蛋白以及应用
BR112021004141A2 (pt)	2018-09-06	2021-05-25	The Trustees Of The University Of Pennsylvania	anticorpo dependente de ph que se liga especificamente a c5 humano, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema complemento de um indivíduo, célula, e, animal não humano geneticamente modificado.
TWI869528B (zh)	2020-01-13	2025-01-11	美商威特拉公司	C5ar1抗體分子及其用途
JP7535591B2 (ja) *	2020-03-27	2024-08-16	インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	コロナウイルス感染の処置のためのＣ５ａのインヒビター
TW202208427A (zh)	2020-05-06	2022-03-01	德商因夫萊亞斯有限公司	人源化抗ｃ５ａ抗體
JP7674399B2 (ja) *	2020-06-24	2025-05-09	スタイドソン・（ベイジン）・バイオファーマシューティカルズ・カンパニー・リミテッド	Ｃ５ａを特異的に認識する抗体およびその使用
MX2023008302A (es)	2021-01-13	2023-09-25	Visterra Inc	Anticuerpos humanizados contra el receptor 1 del componente 5a del complemento y métodos de uso de estos.
WO2023050233A1 (en) *	2021-09-29	2023-04-06	The Trustees Of The University Of Pennsylvania	Humanized anti-c5a antibodies and uses thereof
CN116670288A (zh) *	2021-12-22	2023-08-29	舒泰神（北京）生物制药股份有限公司	一种分离的抗C5a抗体及其制剂与应用
WO2023186054A1 (zh) *	2022-04-02	2023-10-05	舒泰神（北京）生物制药股份有限公司	特异性识别c5a的抗体及其应用
WO2024245527A1 (en)	2023-05-26	2024-12-05	Inflarx Gmbh	Treatment of pneumonia and ards with inhibitors of c5a and il-6 activity
US12180274B2 (en)	2023-05-26	2024-12-31	Inflarx Gmbh	Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
TW202535938A (zh)	2023-10-17	2025-09-16	德商拜恩迪克公司	專一性結合ｃｄ３之抗原結合蛋白及其醫藥用途
WO2025082594A1 (en)	2023-10-17	2025-04-24	BioNTech SE	Antigen binding proteins specifically binding to cd3 and their use in medicine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4704355A (en)	1985-03-27	1987-11-03	New Horizons Diagnostics Corporation	Assay utilizing ATP encapsulated within liposome particles
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
CA2025907A1 (en)	1989-09-21	1991-03-22	Franklin D. Collins	Method of transporting compositions across the blood brain barrier
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
US6121022A (en)	1995-04-14	2000-09-19	Genentech, Inc.	Altered polypeptides with increased half-life
US6277375B1 (en)	1997-03-03	2001-08-21	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
US6673346B1 (en) *	1999-08-31	2004-01-06	The Regents Of The University Of Michigan	Compositions and methods for the treatment of sepsis
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
EP1878441B1 (en) *	2001-08-17	2018-01-24	Genentech, Inc.	Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
CN101387646B (zh) *	2001-08-17	2016-08-10	建南德克公司	结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
WO2003074679A2 (en) *	2002-03-01	2003-09-12	Xencor	Antibody optimization
JP2005535572A (ja) *	2002-04-12	2005-11-24	メディミューン，インコーポレーテッド	組換え抗インターロイキン−９抗体
EP2327725A1 (en) *	2009-11-26	2011-06-01	InflaRx GmbH	Anti-C5a binding moieties with high blocking activity
EA028899B1 (ru)	2010-04-30	2018-01-31	Алексион Фармасьютикалз, Инк.	АНТИ-C5a-АНТИТЕЛА И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ

2009
- 2009-11-26 EP EP09014745A patent/EP2327725A1/en not_active Withdrawn
2010
- 2010-11-26 PH PH1/2012/501243A patent/PH12012501243A1/en unknown
- 2010-11-26 PL PL10782561T patent/PL2504362T3/pl unknown
- 2010-11-26 EP EP16199344.9A patent/EP3181582B1/en active Active
- 2010-11-26 CN CN201080062363.8A patent/CN102741283B/zh active Active
- 2010-11-26 CN CN201510333262.4A patent/CN105037541A/zh active Pending
- 2010-11-26 BR BR112012012514-1A patent/BR112012012514B1/pt active IP Right Grant
- 2010-11-26 EP EP20153768.5A patent/EP3670532A1/en not_active Withdrawn
- 2010-11-26 RS RS20200194A patent/RS59955B1/sr unknown
- 2010-11-26 EA EA201200795A patent/EA022759B1/ru unknown
- 2010-11-26 LT LTEP16199344.9T patent/LT3181582T/lt unknown
- 2010-11-26 LT LTEP10782561.4T patent/LT2504362T/lt unknown
- 2010-11-26 CA CA2780520A patent/CA2780520C/en active Active
- 2010-11-26 PE PE2012000715A patent/PE20130314A1/es active IP Right Grant
- 2010-11-26 AU AU2010324141A patent/AU2010324141B2/en active Active
- 2010-11-26 NZ NZ600348A patent/NZ600348A/en unknown
- 2010-11-26 PT PT107825614T patent/PT2504362T/pt unknown
- 2010-11-26 PT PT161993449T patent/PT3181582T/pt unknown
- 2010-11-26 DK DK10782561.4T patent/DK2504362T3/en active
- 2010-11-26 PL PL16199344T patent/PL3181582T3/pl unknown
- 2010-11-26 SI SI201031368A patent/SI2504362T1/sl unknown
- 2010-11-26 WO PCT/EP2010/007197 patent/WO2011063980A1/en not_active Ceased
- 2010-11-26 SI SI201031978T patent/SI3181582T1/sl unknown
- 2010-11-26 MX MX2012006060A patent/MX2012006060A/es active IP Right Grant
- 2010-11-26 DK DK16199344.9T patent/DK3181582T3/da active
- 2010-11-26 ES ES16199344T patent/ES2773725T3/es active Active
- 2010-11-26 ES ES10782561.4T patent/ES2613352T3/es active Active
- 2010-11-26 KR KR1020197009756A patent/KR102112969B1/ko active Active
- 2010-11-26 KR KR1020187008236A patent/KR20180034690A/ko not_active Ceased
- 2010-11-26 RS RS20170025A patent/RS55571B1/sr unknown
- 2010-11-26 SM SM20200106T patent/SMT202000106T1/it unknown
- 2010-11-26 US US13/512,334 patent/US8802096B2/en active Active
- 2010-11-26 HR HRP20170041TT patent/HRP20170041T1/hr unknown
- 2010-11-26 JP JP2012540323A patent/JP6104605B2/ja active Active
- 2010-11-26 KR KR1020127016454A patent/KR101844611B1/ko active Active
- 2010-11-26 HU HUE16199344A patent/HUE049376T2/hu unknown
- 2010-11-26 HU HUE10782561A patent/HUE032543T2/en unknown
- 2010-11-26 SM SM20170054T patent/SMT201700054T1/it unknown
- 2010-11-26 EP EP10782561.4A patent/EP2504362B1/en active Active
2012
- 2012-05-18 CL CL2012001304A patent/CL2012001304A1/es unknown
- 2012-05-21 IL IL219911A patent/IL219911A/en active IP Right Grant
2014
- 2014-06-27 US US14/317,968 patent/US9073983B2/en active Active
2015
- 2015-06-03 US US14/729,865 patent/US9458233B2/en active Active
- 2015-12-02 JP JP2015235562A patent/JP6591272B2/ja active Active
2016
- 2016-09-16 US US15/267,902 patent/US10774136B2/en active Active
2017
- 2017-01-12 CY CY20171100048T patent/CY1118463T1/el unknown
- 2017-01-24 SM SM201700054T patent/SMT201700054B/it unknown
- 2017-11-27 JP JP2017226849A patent/JP2018080170A/ja active Pending
2019
- 2019-04-16 JP JP2019077667A patent/JP2019163266A/ja active Pending
2020
- 2020-02-12 HR HRP20200241TT patent/HRP20200241T1/hr unknown
- 2020-02-19 CY CY20201100151T patent/CY1122674T1/el unknown
2025
- 2025-06-25 FR FR25C1024C patent/FR25C1024I1/fr active Active
- 2025-07-09 NL NL301334C patent/NL301334I2/nl unknown

Also Published As

Publication number	Publication date
HRP20200241T1 (hr)	2020-06-12
EP3181582A1 (en)	2017-06-21
US20120231008A1 (en)	2012-09-13
PH12012501243A1 (en)	2012-11-05
JP2016074721A (ja)	2016-05-12
WO2011063980A1 (en)	2011-06-03
KR20190039357A (ko)	2019-04-10
KR101844611B1 (ko)	2018-04-02
RS59955B1 (sr)	2020-03-31
KR102112969B1 (ko)	2020-05-19
NZ600348A (en)	2014-01-31
KR20120089346A (ko)	2012-08-09
CN102741283A (zh)	2012-10-17
SI2504362T1 (sl)	2017-03-31
AU2010324141B2 (en)	2014-04-10
US9073983B2 (en)	2015-07-07
AU2010324141A1 (en)	2012-06-21
MX2012006060A (es)	2012-06-19
US9458233B2 (en)	2016-10-04
PT3181582T (pt)	2020-03-03
CY1118463T1 (el)	2017-07-12
EA201200795A1 (ru)	2013-04-30
EA022759B1 (ru)	2016-02-29
SI3181582T1 (sl)	2020-03-31
DK3181582T3 (da)	2020-02-24
CN102741283B (zh)	2015-07-15
RS55571B1 (sr)	2017-05-31
JP2013512209A (ja)	2013-04-11
EP3181582B1 (en)	2020-01-29
PE20130314A1 (es)	2013-04-03
CA2780520A1 (en)	2011-06-03
US8802096B2 (en)	2014-08-12
BR112012012514A2 (pt)	2020-07-28
LT3181582T (lt)	2020-02-25
BR112012012514B1 (pt)	2022-10-04
US20170002067A1 (en)	2017-01-05
EP2327725A1 (en)	2011-06-01
DK2504362T3 (en)	2017-01-30
HRP20170041T1 (hr)	2017-03-10
HUE032543T2 (en)	2017-10-30
ES2773725T3 (es)	2020-07-14
PL3181582T3 (pl)	2020-06-01
FR25C1024I1 (fr)	2025-08-01
HUE049376T2 (hu)	2020-09-28
EP2504362B1 (en)	2016-11-23
US20150266949A1 (en)	2015-09-24
NL301334I2 (nl)	2025-09-10
CN105037541A (zh)	2015-11-11
CA2780520C (en)	2021-11-23
SMT201700054T1 (it)	2017-03-08
PL2504362T3 (pl)	2017-08-31
IL219911A0 (en)	2012-07-31
JP2018080170A (ja)	2018-05-24
ES2613352T3 (es)	2017-05-24
IL219911A (en)	2017-03-30
KR20180034690A (ko)	2018-04-04
PT2504362T (pt)	2017-01-18
US20140314772A1 (en)	2014-10-23
JP6591272B2 (ja)	2019-10-16
US10774136B2 (en)	2020-09-15
JP6104605B2 (ja)	2017-03-29
SMT201700054B (it)	2017-03-08
CY1122674T1 (el)	2021-03-12
SMT202000106T1 (it)	2020-03-13
EP3670532A1 (en)	2020-06-24
EP2504362A1 (en)	2012-10-03
LT2504362T (lt)	2017-02-10
JP2019163266A (ja)	2019-09-26

Publication	Publication Date	Title
CL2012001304A1 (es)	2012-08-03	Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas.
CL2013000390A1 (es)	2014-03-21	Anticuerpo monoclonal que se une al peptido beta amiloide n3pglu o fragmento de union a antigeno del mismo; composicion farmaceutica que lo comprende; y su uso para tratar la enfermedad de alzheimer.
CL2014002750A1 (es)	2015-04-06	Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
CL2014000590A1 (es)	2014-10-17	Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia.
CL2012000620A1 (es)	2013-09-06	Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
CL2012002896A1 (es)	2013-08-09	Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva.
EP2740489A4 (en)	2015-03-04	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF PANCREATIC CARCINOMA
CL2013002811A1 (es)	2014-02-28	Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion.
CL2013000843A1 (es)	2014-03-07	Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso.
CL2013001654A1 (es)	2014-03-28	Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2013000097A1 (es)	2015-01-09	Composicion farmaceutica combinada que incluye una forma activada potenciada de un anticuerpo de la proteina s-100 y una forma activada potenciada de un anticuerpo anti tnf-alfa; metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal.
CL2014000758A1 (es)	2014-08-22	Anticuerpo aislado o fragmento del mismo que se une especificamente a erbb3; composicion farmaceutica que lo comprende; y su uso para inhibir el crecimiento tumoral.
PE20161032A1 (es)	2016-10-19	Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
UA118441C2 (uk)	2019-01-25	Антитіло, що розпізнає альфа-синуклеїн
BR112012022210A2 (pt)	2017-09-05	anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
JP2014043446A5 (es)	2014-05-08
EP2532367A4 (en)	2014-05-28	PHARMACEUTICAL AGENT FOR THE TREATMENT AND / OR PREVENTION OF CANCER
CL2011002877A1 (es)	2012-05-25	Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2012002438A1 (es)	2013-09-13	Anticuerpo aislado que se une a peptido ciclico derivado de peptido betaamiloide (ab); inmunoconjugado que comprende dicho anticuerpo; metodo para tratar o prevenir enfermedad de alzheimer que comprende el anticuerpo antes mencionado; kit que comprende el anticuerpo.
EP2838549A4 (en)	2015-12-23	MEDICINAL PRODUCT FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC FAT TEMPERATURE DISEASE
CL2008000887A1 (es)	2008-05-30	Compuestos derivados de 3-hidroxi-1h-pirimidin-4-ona o 3-hidroxi-piran-4-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad neurodegenerativa causada por la presencia de
CR20130632A (es)	2014-02-04	El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
UA123202C2 (uk)	2021-03-03	Антитіло до тау-білка і його застосування
BR112012002265A2 (pt)	2016-06-14	composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
BRPI0814346A2 (pt)	2015-01-20	Uso de imidazoquinolinas para o tratamento de doenças dependentes de egfr ou doenças que adquiriram resistência a agentes que são direcionados aos membros da família de egfr.